RSS-Feed abonnieren
DOI: 10.1055/s-2008-1027406
© Georg Thieme Verlag KG Stuttgart · New York
Die Rolle epigenetischer Veränderungen in kolorektalen Karzinomen und ihren Vorläuferläsionen
Epigenetic Alterations in Colorectal Carcinomas and Precancerous LesionsPublikationsverlauf
eingereicht: 4.1.2008
angenommen: 28.3.2008
Publikationsdatum:
20. Oktober 2008 (online)

Zusammenfassung
Das kolorektale Karzinom stellt den dritthäufigsten malignen Tumor weltweit dar mit einer Inzidenz von 570 000 pro Jahr. Anhand der molekularen Veränderungen können (sporadische) kolorektale Karzinome in zwei unterschiedliche Phänotypen unterteilt werden. Der genetische Phänotyp, der ca. 50 – 70 % aller sporadischen kolorektalen Karzinome ausmacht, ist charakterisiert durch eine chromosomale Instabiliät (CIN) mit der klassischen Adenom-Karzinom-Sequenz, hervorgerufen durch Alterationen im APC-βCatenin-Weg mit p53-Mutationen, SMAD-Genveränderungen und LOH (loss of heterozygosity) auf 5q, 17 p 18q. Demgegenüber steht der CpG Island-Methylatorphänotyp (CIMP+), der eine epigenetische Inaktivierung von Tumorsuppressorgenen aufweist, die bei familiären Karzinomsyndromen typischerweise Keimbahnmutationen aufweisen wie z. B. Rb, VHL, hMLH1, p16 oder BRCA. Häufig gehen kolorektale Karzinome vom CIMP+-Typ mit einer Mikrosatelliteninstabilität (MSI+) einher infolge einer Promotormethylierung des Mismatch-Repair-Gens hMLH1. Weiterhin sind sie vermehrt im proximalen rechtsseitigen Kolon lokalisiert und nicht selten High-Grade-Karzinome mit muzinöser oder siegelringzelliger Differenzierung.
Abstract
Colorectal carcinomas are the third most common malignant tumours worldwide with an incidence of 570,000 per year. According to their molecular mechanisms, sporadic colorectal carcinomas can be divided into two different phenotypes. The genetic phenotype, 50 to 70 % of all sporadic colorectal carcinomas, is characterised by a chromosomal instability (CIN) with the classical adenoma-carcinoma sequence due to alteration of the APC-βcatenin pathway with p53 mutations, SMAD alterations and LOH (loss of heterozygositiy) of 5q, 17 p 18q. On the other, the CpG island methylator phenotype (CIMP+) was described with an epigenetic inactivation of tumour suppressor genes that are typically inactivated by germline mutations in familiar cancer syndromes, e. g., Rb, VHL, hMLH1, p16 or BRCA. Colorectal carcinomas of the CIMP+ type often show a high microsatellite instability (MSI+) caused by aberrant promoter methylation of the missmatch repair gene hMLH1. Further CIMP+ are located in the proximal right-side colon and show a poor grading with mucinous or signet-cell differentiation.
Schlüsselwörter
Kolorektales Karzinom - Adenom - Promotormethylierung - CIN - CIMP
Key words
colorectal carcinoma - adenoma - promotor methylation - CIN - CIMP
Literatur
- 1
Aaltonen L A, Peltomaki P, Leach F S. et al .
Clues to the pathogenesis of familial colorectal cancer.
Science.
1993;
260
812-816
MissingFormLabel
- 2
Bai A HC, Tong J HM, To K F. et al .
Promoter methylation of tumor-related genes in the progression of colorectal neoplasia.
Int J Cancer.
2004;
112
846-853
MissingFormLabel
- 3
Baylin S B, Esteller M, Rountree M R. et al .
Aberrant pattern of DNA methylation, chromatin formation and gene expression in cancer.
Hum Mol Genet.
2001;
10
687-692
MissingFormLabel
- 4
Bird A, Wolffe A P.
Methylation-induced repression- belts, braces and chromation.
Cell.
1999;
99
451-454
MissingFormLabel
- 5
Dong S M, Lee E J, Park C K. et al .
Progressive methylation during the serrated neoplasia pathway of the colorectum.
Mod Pathol.
2005;
18
170-178
MissingFormLabel
- 6 Ehrlich M. DNA hypomethylation and cancer. Natick DNA Alteratins in Cancer: Genetic and Epigenetic Changes Natick; Eaton Publishing 2000: 273-291
MissingFormLabel
- 7
Engeland van M, Roemen G MJM, Brink M. et al .
K-ras and RASSF1A promoter methylation in colorectal cancer.
Oncogene.
2002;
21
3792-3795
MissingFormLabel
- 8
Esteller M, Tortola S, Toyota M. et al .
Hypermethylation-associated inactivation of p14ARF is independent pf p16INK4a methylation
and mutational status.
Cancer Res.
2000;
60
129-133
MissingFormLabel
- 9
Esteller M, Hamilton S R, Buger P C. et al .
Inactivation of the DNA repair gene O 6-methylguanine-DNA methyltransferase by promoter
methylation is a common event in primary human neoplasia.
Cancer Res.
1999;
59
793-797
MissingFormLabel
- 10
Esteller M, Toyota M, Sanchez-Cespedes M. et al .
Inactivation of the DNA repair gene O 6-methylguanine-DNA methyltransferase by promoter
hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.
Cancer Res.
2000;
60
2368-2371
MissingFormLabel
- 11
Esteller M, Risques R A, Toyota M. et al .
Promoter hypermethylation of the DNA repair O 6-methylguanine-DNA methyltransferase
is associated with the presence of G:C to A:T transition mutations in p53 in human
colorectal tumorigenesis.
Cancer Res.
2001;
61
4689-4692
MissingFormLabel
- 12
Fodde R, Kuipers J, Rosenberg C. et al .
Mutations in the APC tumour suppressor gene cause chromosomal instability.
Nat Cell Biol.
2001;
3
433-438
MissingFormLabel
- 13
Hall M, Peters G.
Genetic alterations of cyclins, cyclin-dependent kinases and Cdk inhibitors in human
cancer.
Adv Cancer Res.
1996;
68
67-108
MissingFormLabel
- 14
Hendrich B, Bird A.
Mammalian methyltransferases and methyl CpG-binding domains: proteins involved in
DNA methylation.
Curr Top Microbiol Immunol.
2000;
249
55-74
MissingFormLabel
- 15
Hibi K, Nakayama H, Koike M. et al .
Colorectal cancers with both p16 and p14 methylation show invasive characteristics.
Jpn J Cancer Res.
2002;
93
883-887
MissingFormLabel
- 16
Jass J R.
Classification of colorectal cancer based on correlation of clinical, morphological
and molecular features.
Histopathology.
2007;
50
113-130
MissingFormLabel
- 17
Karpf A R, Jones D A.
Reactivating the expression of methylation silenced genes in human cancers.
Oncogene.
2002;
35
5496-5503
MissingFormLabel
- 18
Kim H C, Roh S A, GA I H. et al .
CpG island methylation as an early event during adenoma progression in carcinogenesis
of sporadic colorectal cancer.
J Gastroenterol Hepatol.
2005;
20
1920-1926
MissingFormLabel
- 19
Lee S, Hwang K S, Lee H J. et al .
Aberrant CpG island hypermethylation of multiple genes in colorectal colorectal neoplasia.
Lab Invest.
2004;
84
884-893
MissingFormLabel
- 20
Liggett W H, Sidransky Jr D.
Role of the p16 tumor suppressor gene in cancer.
J Clin Oncol.
1998;
16
1197-1206
MissingFormLabel
- 21
Lind G E, Thorstensen L, Lovig T. et al .
A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer
cell lines.
Mol Cancer.
2004;
3
28
MissingFormLabel
- 22
Mäkinen M J.
Colorectal serrated adenocarcinoma.
Histopathology.
2007;
50
131-150
MissingFormLabel
- 23
Raveh T, Kimchi A.
DAP kinase – a proapoptotic gene that functions as a tumor suppressor.
Exp Cell Res.
2001;
264
185-192
MissingFormLabel
- 24
Shivakumar L, Minna J D, Sakamaki T. et al .
The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D 1
accumulation.
Mol Cell Biol.
2002;
22
4309-4318
MissingFormLabel
- 25
Song M S, Song S J, Ayad N G. et al .
The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex.
Nat Cell Biol.
2004;
6
129-137
MissingFormLabel
- 26
Sato F, Harpaz N, Shibata D. et al .
Hypermethylation of the p14ARF gene in ulcerative colitis-associated colorectal carcinogenesis.
Cancer Res.
2002;
62
1148-1151
MissingFormLabel
- 27
Thibodeau S N, Bren G, Schaid D.
Microsatellite instability in cancer of the proximal colon.
Science.
1993;
260
816-819
MissingFormLabel
- 28
Toyota M, Ahuja N, Ohe-Toyota M. et al .
CpG island methylator phenotype in colorectal cancer.
Proc Natl Acad Sci USA.
1999;
96
8681-8686
MissingFormLabel
- 29
Vogelstein B, Fearon E R, Hamilton S R. et al .
Genetic alterations during colorectal-tumor development.
N Engl J Med.
1988;
19
525-532
MissingFormLabel
- 30
Whitehall V LJ, Walsh M D, Young J. et al .
Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal
cancer with low-level DNA microsatellite instability.
Cancer Res.
2001;
61
827-830
MissingFormLabel
Dr. Iris Tischoff
Institut für Pathologie der Ruhr-Universität Bochum an der BG Universitätsklinik Bergmannsheil
Bürkle-de-la-Camp-Platz 1
44789 Bochum
Telefon: ++ 49 / 234 / 3024955
Telefon: ++ 49 / 234 / 3024809
eMail: iris.tischoff@rub.de